Get the Stockscreener App
6.98
0.92%
-0.065
After Hours:
7.04
0.06
+0.86%
Alpha Cognition Inc stock is traded at $6.98, with a volume of 86,236.
It is down -0.92% in the last 24 hours and down -28.78% over the past month.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
See More
Previous Close:
$7.045
Open:
$7.05
24h Volume:
86,236
Relative Volume:
1.19
Market Cap:
$147.26M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-2.4664
EPS:
-2.83
Net Cash Flow:
$-7.41M
1W Performance:
-5.03%
1M Performance:
-28.78%
6M Performance:
+44.52%
1Y Performance:
+0.00%
1-Day Range:
$6.80
$7.2881
1-Week Range:
$6.7954
$7.80
52-Week Range:
$3.75
$11.54
Alpha Cognition Inc Stock (ACOG) Company Profile
Name
Alpha Cognition Inc
Sector
Industry
Phone
(858) 344-4375
Address
1200-750 W PENDER ST, VANCOUVER
Compare ACOG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
6.98 | 147.26M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | H.C. Wainwright | Buy |
Alpha Cognition Inc Stock (ACOG) Latest News
Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings - The AI Journal
Risk adjusted return profile for Alpha Cognition Inc. analyzedQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
Can technical indicators confirm Alpha Cognition Inc.’s reversalJuly 2025 Market Mood & Weekly High Potential Stock Alerts - newser.com
Real time pattern detection on Alpha Cognition Inc. stock2025 Analyst Calls & Daily Profit Maximizing Trade Tips - newser.com
Is Alpha Cognition Inc. stock attractive for long term wealth buildingGold Moves & Short-Term Trading Alerts - newser.com
Is Alpha Cognition Inc. stock a smart buy before Fed meetingMarket Trend Report & Fast Exit Strategy with Risk Control - newser.com
How high can Alpha Cognition Inc. stock goWeekly Gains Report & Weekly Return Optimization Alerts - newser.com
Will Alpha Cognition Inc. outperform the marketTrade Risk Report & Community Verified Swing Trade Signals - newser.com
Statistical indicators supporting Alpha Cognition Inc.’s strengthTrade Entry Report & Risk Managed Investment Strategies - newser.com
Strategies to average down on Alpha Cognition Inc.July 2025 Trends & Risk Managed Investment Signals - newser.com
Opaleye Management Inc. Acquires Significant Stake in Alpha Cognition Inc. - GuruFocus
Will Alpha Cognition Inc. stock outperform Nasdaq indexMarket Volume Summary & Real-Time Buy Zone Alerts - newser.com
How to escape a deep drawdown in Alpha Cognition Inc.Trade Risk Report & Free Long-Term Investment Growth Plans - newser.com
Multi asset correlation models including Alpha Cognition Inc.July 2025 Analyst Calls & AI Based Buy and Sell Signals - newser.com
Is Alpha Cognition Inc a good long term investmentRSI Overbought/Oversold & We Spotted the Next Tesla – See Inside - earlytimes.in
Alpha Cognition to Present Clinical Data at ASCP Annual Meeting - Business Wire
Published on: 2025-10-05 06:09:34 - newser.com
Is Alpha Cognition Inc. stock a safe buy before earningsTake Profit & Daily Profit Focused Stock Screening - newser.com
Alpha Cognition Inc. (NASDAQ:ACOG) Sees Significant Decrease in Short Interest - Defense World
Alpha Cognition Secures $35 Million in Oversubscribed Public Offering to Accelerate Neurodegenerative Disease Treatment Commercialization - citybuzz
Alpha Cognition prices $35M public offering of common shares - msn.com
Detecting support and resistance levels for Alpha Cognition Inc.Quarterly Portfolio Summary & Reliable Intraday Trade Plans - newser.com
Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares - BioSpace
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares - BioSpace
Alpha Cognition raises $35 million in oversubscribed public offering By Investing.com - Investing.com Australia
Alpha Cognition announces proposed public offering of shares By Investing.com - Investing.com Nigeria
Alpha Cognition raises $35 million in oversubscribed public offering - Investing.com
Alpha Cognition Inc announces pricing of oversubscribed underwritten public offering of 5.6 mln common shares at $6.25 per share - MarketScreener
$35M Oversubscribed Offering: Alpha Cognition Accelerates ZUNVEYL Alzheimer's Drug Commercial Launch - Stock Titan
Alpha Cognition announces proposed public offering of shares - Investing.com India
Alpha Cognition stock falls after announcing public offering plan By Investing.com - Investing.com Australia
Alpha Cognition stock falls after announcing public offering plan - Investing.com
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Cognition Inc Stock (ACOG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MERTZ PHILLIP JOSEPH | Director |
Aug 18 '25 |
Sale |
9.00 |
27,778 |
250,002 |
22,462 |
| MERTZ LEONARD POWELL | Director |
Aug 18 '25 |
Buy |
9.00 |
27,778 |
250,002 |
121,503 |
| McFadden Michael E. | Chief Executive Officer |
Nov 13 '24 |
Buy |
5.75 |
2,608 |
14,996 |
14,142 |
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):